NR1H4 and metabolic dysfunction-associated steatotic liver disease: OCA, an FXR agonist derived from chenodeoxycholic acid, has shown promise in the treatment of non-alcoholic steatohepatitis (MASH) and has improved the histological characteristics of MASH, particularly with regard to the NAFLD Activity Score (NAS) [229,230].